{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:19:27Z","timestamp":1787671167201,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:p>Melanoma is an aggressive form of skin cancer associated with significant morbidity and mortality. Although commonly seen in dermatologist clinics, orthopaedic surgeons must be aware of these lesions in various ways. The five common musculoskeletal manifestations of melanoma will be discussed as well as the epidemiology, pathogenesis, diagnosis, staging, treatment, and prognosis of melanoma. With an index of suspicion and awareness of melanoma, a thorough history and detailed physical examination are critical in establishing a diagnosis. An adequately performed biopsy will confirm the diagnosis and assist in determining prognosis. As ambassadors of health for the musculoskeletal system, orthopaedic surgeons may be the first practitioners to encounter a pigmented skin lesion. Acral pigmented lesions should prompt a concern for melanoma with appropriate subsequent steps for management to follow. Finally, it is important for every orthopaedic surgeon to consider disseminated melanoma in the differential diagnosis of a skeletal metastasis, a deep soft-tissue mass, or lymphadenopathy in a patient with a previous history of a melanotic lesion.<\/jats:p>","DOI":"10.5435\/jaaos-d-18-00757","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T16:03:49Z","timestamp":1582646629000},"page":"e540-e549","source":"Crossref","is-referenced-by-count":1,"title":["Orthopaedic Manifestations of Melanoma and Their Management"],"prefix":"10.5435","volume":"28","author":[{"given":"Matthew R.","family":"DiCaprio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa M.","family":"Abousayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi L. R.","family":"Kambam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"R1-20230714","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.clindermatol.2009.06.021","article-title":"Melanoma epidemic: Facts and controversies","volume":"28","author":"Erickson","year":"2010","journal-title":"Clin Dermatol"},{"key":"R4-20230714","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4065\/81.4.500","article-title":"Cutaneous malignant melanoma","volume":"81","author":"Cummins","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R6-20230714","first-page":"3081","article-title":"Primary locations of malignant melanoma lesions depending on patients' gender and age","volume":"18","author":"Stanienda-Sok\u00f3\u0142","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"R7-20230714","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"key":"R8-20230714","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ng0994-15","article-title":"Germline p16 mutations in familial melanoma","volume":"8","author":"Hussussian","year":"1994","journal-title":"Nat Genet"},{"key":"R9-20230714","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annepidem.2008.04.006","article-title":"Sunburns and risk of cutaneous melanoma: Does age matter? A comprehensive meta-analysis","volume":"18","author":"Dennis","year":"2008","journal-title":"Ann Epidemiol"},{"key":"R10-20230714","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.sder.2010.10.005","article-title":"Epidemiology of melanoma","volume":"29","author":"Rigel","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"R11-20230714","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1200\/JCO.2005.11.108","article-title":"Risk factors and individual probabilities of melanoma for whites","volume":"23","author":"Cho","year":"2005","journal-title":"J Clin Oncol"},{"key":"R12-20230714","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1001\/jama.294.13.1647","article-title":"Clinicopathological features of and risk factors for multiple primary melanomas","volume":"294","author":"Ferrone","year":"2005","journal-title":"JAMA"},{"key":"R13-20230714","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1940-6207.CAPR-09-0108","article-title":"Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma","volume":"3","author":"Olsen","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"R14-20230714","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0560.1988.tb00544.x","article-title":"Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors","volume":"15","author":"Wick","year":"1988","journal-title":"J Cutan Pathol"},{"key":"R15-20230714","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint committee on cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R16-20230714","doi-asserted-by":"crossref","first-page":"583748","DOI":"10.1155\/2010\/583748","article-title":"From melanocyte to metastatic malignant melanoma","volume":"2010","author":"Bandarchi","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"R17-20230714","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/107327480901600305","article-title":"Sentinel lymph node biopsy for melanoma: Indications and rationale","volume":"16","author":"Phan","year":"2009","journal-title":"Cancer Control"},{"key":"R18-20230714","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11912-019-0798-y","article-title":"Sentinel lymph node biopsy and complete lymph node dissection for melanoma","volume":"21","author":"Falk Delgado","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"R19-20230714","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1002\/cam4.2358","article-title":"Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study","volume":"8","author":"Tejera-Vaquerizo","year":"2019","journal-title":"Cancer Med"},{"key":"R20-20230714","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"R21-20230714","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1245\/s10434-014-4211-7","article-title":"Sentinel lymph node biopsy in thick-melanoma patients (N=350): What is its prognostic role?","volume":"22","author":"Ribero","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R22-20230714","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1245\/s10434-018-07094-w","article-title":"Subungual melanoma of the hand","volume":"26","author":"Chakera","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"R23-20230714","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.det.2012.04.009","article-title":"Surgical treatment of malignant melanoma: Practical guidelines","volume":"30","author":"Levine","year":"2012","journal-title":"Dermatol Clin"},{"key":"R24-20230714","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.amjoto.2018.06.007","article-title":"Is imaging of the brain necessary at diagnosis for cutaneous head and neck melanomas?","volume":"39","author":"Janz","year":"2018","journal-title":"Am J Otolaryngol"},{"key":"R25-20230714","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3322\/caac.20074","article-title":"The evolution of melanoma diagnosis: 25 years beyond the ABCDs","volume":"60","author":"Rigel","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R26-20230714","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1067\/mjd.2003.63","article-title":"Acral lentiginous melanoma mimicking benign disease: The emory experience","volume":"48","author":"Soon","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"R27-20230714","first-page":"1051","article-title":"Controversies in acral lentiginous melanoma","volume":"28","author":"Stalkup","year":"2002","journal-title":"Dermatol Surg"},{"key":"R28-20230714","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1177\/107110070602700908","article-title":"Diagnosis and treatment of malignant melanoma of the foot","volume":"27","author":"Gray","year":"2006","journal-title":"Foot Ankle Int"},{"key":"R29-20230714","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"R30-20230714","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2106\/00004623-197860050-00009","article-title":"Skeletal metastases of melanoma","volume":"60","author":"Stewart","year":"1978","journal-title":"J Bone Joint Surg Am"},{"key":"R31-20230714","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1007\/s11999-014-3761-0","article-title":"Operative management of metastatic melanoma in bone may require en bloc resection of disease","volume":"472","author":"Krygier","year":"2014","journal-title":"Clin Orthop Relat Res"},{"key":"R32-20230714","first-page":"246","article-title":"Surgical treatment of skeletal metastases in 31 melanoma patients","volume":"78","author":"Wedin","year":"2012","journal-title":"Acta Orthop Belg"},{"key":"R33-20230714","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3171\/2009.1.SPINE08657","article-title":"Outcome following decompressive surgery for different histological types of metastatic tumors causing epidural spinal cord compression: Clinical article","volume":"11","author":"Chaichana","year":"2009","journal-title":"J Neurosurg Spine"},{"key":"R34-20230714","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1227\/NEU.0000000000000790","article-title":"Prognostic factors influencing the outcome of 64 consecutive patients undergoing surgery for metastatic melanoma of the spine","volume":"77","author":"Sellin","year":"2015","journal-title":"Neurosurgery"},{"key":"R35-20230714","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23151","article-title":"Metastases to soft tissue: A review of 118 cases over a 30-year period","volume":"112","author":"Plaza","year":"2008","journal-title":"Cancer"},{"key":"R36-20230714","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1054\/bjoc.2000.1628","article-title":"Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts)","volume":"84","author":"Angezaal","year":"2001","journal-title":"Br J Cancer"},{"key":"R37-20230714","first-page":"CD004835","article-title":"Surgical excision margins for primary cutaneous melanoma","author":"Sladden","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R38-20230714","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/(SICI)1096-9098(199908)71:4<209::AID-JSO1>3.0.CO;2-2","article-title":"Metastatectomy for recurrent stage IV melanoma","volume":"71","author":"Ollila","year":"1999","journal-title":"J Surg Oncol"},{"key":"R39-20230714","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R40-20230714","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"R41-20230714","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R42-20230714","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): Secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"Coens","year":"2017","journal-title":"Lancet Oncol"},{"key":"R43-20230714","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"R44-20230714","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.smim.2016.01.001","article-title":"Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?","volume":"28","author":"Robert","year":"2016","journal-title":"Semin Immunol"},{"key":"R45-20230714","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positivemelanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"R46-20230714","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1634\/theoncologist.2014-0429","article-title":"Adjusting for the confounding effects of treatment switching-the BREAK-3 trial: Dabrafenib versus dacarbazine","volume":"20","author":"Latimer","year":"2015","journal-title":"Oncologist"},{"key":"R47-20230714","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus Trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 6","key":"R48-20230714","doi-asserted-by":"crossref","first-page":"vi22","DOI":"10.1093\/annonc\/mdp257","article-title":"Surgery and radiotherapy in the treatment of cutaneous melanoma","volume":"20","author":"Testori","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-18-00757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:39:59Z","timestamp":1787668799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-18-00757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":45,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-18-00757","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]}}}